Chordia Therapeutics <190A> announced its financial results for the fiscal year ending in August 2024 on the 11th. There was no business income (2.5 billion yen of business income in the previous year), operating loss was 1.801 billion yen (profit of 0.212 billion yen), ordinary loss was 1.824 billion yen (profit of 0.225 billion yen), and net loss for the period was 1.827 billion yen (profit of 0.223 billion yen).
In the current fiscal year, research and development of the pipeline centered around CLK inhibitor drug CTX-712 (referred to as CTX-712) is progressing well. Despite the continued response to the novel coronavirus infection, patient registration for the Phase 1 clinical trial in Japan (with a total of 60 cases: 46 solid cancer cases, 14 blood cancer cases) was completed under the cooperation of the clinical trial period. The results of the Phase 1 clinical trial in Japan were reported at the American Cancer Society meeting in April 2024, showing the safety, efficacy, genome information, and pharmacokinetics of the Phase 1 clinical trial up to November 2023 for 46 solid cancer cases and 14 blood cancer cases. It was shown that CTX-712 is effective against ovarian and blood cancers. Additionally, Phase 1/2 clinical trials for blood cancer in the USA are progressing well, with 20 cases completed by the end of August 2024, and further activities are being undertaken for the progress of the trials. Regarding MALT1 inhibitor drug CTX-177 (referred to as CTX-177), based on the licensing agreement signed with Ono Pharmaceutical <4528> in December 2020, Ono Pharmaceutical is conducting Phase 1 clinical trials in the USA targeting patients with refractory or relapsed non-Hodgkin lymphoma or chronic lymphocytic leukemia. As part of external presentations, an overview of the Phase 1 clinical trial was presented by Ono Pharmaceutical at the American Clinical Oncology meeting in June 2024. For the non-clinical stage CDK12 inhibitor drug CTX-439 (referred to as CTX-439), safety tests and drug manufacturing for the clinical trial have been completed, and preparations for the next phases are currently ongoing. In terms of patents, additional registrations have been made for CTX-712 in 2 countries, totaling 51 registered countries; CTX-177 in 5 countries, totaling 11 registered countries; CTX-439 in 1 country and 1 region, totaling 4 countries and 1 region; and GCN2 inhibitor (GCN2) in 6 countries. Moreover, a biomarker patent (WO2023/190967) for solid cancer has been published for CTX-712, and a new patent application was filed in January 2024.
Regarding the performance forecast for the full year ending in August 2025, no business income is expected to be recorded, with an operating loss of 2.434 billion yen, an ordinary loss of 2.378 billion yen, and a net loss for the period of 2.38 billion yen.
